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Figure 1. Activation of IL-1b in Islets of Patients with Type 2 Diabetes
Glucose, free fatty acids (FFA), and adipokine (leptin) promote b cell production of IL-1b. In turn, IL-1b
induces the production and release of a wide panel of cytokines and chemokines, which recruit macro-
phages. Human islet polypeptide will then activate the macrophage NALP3 inflammasome, enhancing
IL-1b production. IL-1b will also induce itself initiating a vicious cycle.
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Previewsdetermined, its ability to activate the
NALP3 inflammasome adds further evi-
dence for a final effector pathway com-
mon to numerous islet stressors during
type 2 diabetes.428 Cell Metabolism 12, November 3, 2010 ªREFERENCES
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Glycogen metabolism serves as a critical regulator of energy storage and maintenance of blood glucose
levels in a physiological range. In this issue of Cell Metabolism, Bouskila et al. (2010) unexpectedly find
that skeletal muscle glycogen accumulation is principally controlled by the allosteric activation of glycogen
synthase, opening new avenues for investigation.Glycogen is the storage form of carbohy-
drate for virtually every organism from
yeast to mammals. In the 1850s, Claude
Bernard identified a starch-like substancein tissues and called it ‘‘glycogen,’’ or
‘‘sugar former.’’ Since its identification,
research into the regulation of glycogen
metabolism has led to fundamentaldiscoveries in biochemistry that are rele-
vant to nearly every biological system.
The Nobel Laureate Earl Sutherland iden-
tified cAMP as the first secondmessenger
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Previewsduring his studies on epinephrine-induced
glycogenolysis in liver (Sutherland and
Rall, 1958). Additionally, Edwin Krebs
and Edmond Fischer discovered that the
interconversion of glycogen phosphory-
lase b (inactive form) to glycogen phos-
phorylase a (active form) was dependent
on a phosphorylation event (Fischer and
Krebs, 1955), the first description of
a protein kinase for which in part they
received the Nobel Prize. Despite these
significant contributions to enzymology
and signal transduction, the molecular
mechanisms by which hormonal control
of glycogen storage are mediated remain
controversial. In this issue, Bouskila et al.
(2010) provide important evidence that
the allosteric activation of glycogen syn-
thase by glucose-6-phosphate (G6P) is
the principal mechanism by which insulin
stimulates glycogen synthesis in skeletal
muscle.
In skeletal muscle, glycogen synthesis
follows a simple but strictly ordered
process involving multiple enzymes,
resulting in a complex structure. Glycogen
synthase is the rate-limiting enzyme
that catalyzes the addition of glucose resi-
dues to the glycogen chains. Conversely,
glycogen phosphorylase mediates gly-
cogen breakdown, releasing glucose-1-
phosphate which is metabolized to pro-
duce ATP via glycolysis. Both glycogen
synthase and phosphorylase enzymatic
activities are regulated covalently and
allosterically. The phosphorylation of
glycogen synthase on up to nine serine
residues results in the progressive inacti-
vation of the enzyme. Conversely, the
phosphorylation of glycogen phosphory-
lase on a single N-terminal serine residue
increases enzymatic activity. In addition,
both enzymes are allosterically activated
and inhibited by a variety of metabolic
intermediaries (Lawrence and Roach,
1997). The study of glycogen metabolism
has largely focused on the regulation of
glycogen synthase activity. Insulin stimu-
lates glucose flux into skeletal muscle via
GLUT4 transporter translocation, pro-
viding substrate for glycogen elongation
and formation of G6P, which feeds
forward to allosterically activate glycogen
synthase overriding inhibition by phos-
phorylation. Additionally, insulin promotes
the dephosphorylation of glycogen syn-
thase through kinase inactivation and
phosphatase activation. The principal
kinase that regulates glycogen synthaseactivity is glycogen synthase kinase-3
(GSK3), which is inactivated by insulin
through activation of the upstream kinase
Akt/PKB (Cohen, 1998). There is also
a family of proteins that target protein
phosphatase-1 (PP1) to glycogen and
have been proposed to be important
mediators of insulin metabolic action
(Newgard et al., 2001). However, the rela-
tive contributions of covalent versus allo-
steric mechanisms in the control of
glycogen synthase activity by insulin are
incompletely understood.
In the current issue, Bouskila et al.
(2010) provide compelling evidence that
the allosteric activation of glycogen syn-
thase by G6P is the primary mechanism
controlling glycogen accumulation in skel-
etalmuscle. Thisworkbuilds onaprevious
report from the same group using trans-
genic knockinmice in which GSK3a/b iso-
forms had been replaced with mutant
enzymes that could not be phosphory-
lated and inhibited in response to insulin
(Bouskila et al., 2007). Although the cova-
lent dephosphorylation and activation of
glycogen synthase were completely
blocked in the mutant GSK3 knockin ani-
mals, glycogen levels and acute insulin-
stimulated glycogen synthesis were
largely unaffected. These data suggested
that the allosteric activation of glycogen
synthase by increased glucose uptake
and formation of G6P in response to
insulin may be the principal mechanism
controlling glycogen metabolism. To ex-
tend these findings, the authors con-
ducted point mutagenesis and identified
acritical arginine residueonglycogen syn-
thase whose mutation to alanine com-
pletely blocked the allosteric activation of
the enzyme by G6P (Bouskila et al.,
2010). Importantly, the point mutation
had no effect on the solubility of glycogen
synthase, nor its ability to be dephos-
phorylated in vitro or in vivo. Interestingly,
homozygous transgenic knockin mice
containing the mutant glycogen synthase
molecule exhibited a marked reduction
in skeletal muscle glycogen levels and
insulin-stimulated glycogen synthetic
rates. These metabolic changes occurred
despite a comparable dephosphorylation
and activation of glycogen synthase by
insulin in the transgenic versus control
mice. Changes in glycogen synthesis
could not be accounted for by inhibition
of glucose uptake and phosphorylation
or a dysregulation of glycogen phosphor-Cell Metabolism 12,ylase activity. Cumulatively, these results
strongly indicate that allosteric activa-
tion of glycogen synthase resulting from
insulin-stimulated glucose uptake in skel-
etal muscle is the principal controlmecha-
nism regulating glycogen accumulation.
While the current work by Bouskila et al.
(2010) is certainly provocative, several un-
answered questions remain. In addition to
allosteric regulation by G6P, glycogen
synthase activity is also controlled by
phosphorylation on multiple serine resi-
dues. Previously, two groups had gener-
ated transgenic mouse models in which
the principal glycogen-targeting subunit
for PP1 in skeletal muscle had been
ablated (Suzuki et al., 2001; Delibegovic
et al., 2003). Both teams reported
a marked 90% reduction in muscle gly-
cogen levels commensurate with a basal
reduction of total glycogen synthase
activity and the percentage of enzyme in
the active form. The results had been in-
terpreted to indicate that glycogen-tar-
geted PP1 activity was required for the
basal maintenance of glycogen stores,
and potentially mediated the activation
of glycogen synthase by insulin (Delibe-
govic et al., 2003). However, in both
animal models glycogen phosphorylase
activity was significantly elevated (Suzuki
et al., 2001; Delibegovic et al., 2003).
These findings raise the intriguing possi-
bility that glycogen-targeted PP1 may
primarily act as a brake on glycogenolysis
rather than mediating the activation of
glycogen synthase in response to insulin.
One further complication is that in skeletal
muscle, insulin stimulates the transloca-
tion of glycogen synthase from a cytosolic
fraction to the glycogen-containing frac-
tion (Nielsen et al., 2001). Thus, although
Bouskila et al. (2010) have clearly demon-
strated that the allosteric activation of
glycogen synthase byG6P is an important
regulator of glycogen synthetic rates, the
possibility that G6P binding to glycogen
synthase may also impact the enzyme’s
association with glycogen particles has
not been discounted. Clearly, further work
will be required to fully delineate themolec-
ular complexities involved in the regula-
tion of this classical metabolic system.REFERENCES
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